Saliva Test Development for Alzheimer’s Detection

Introduction to Alzheimer’s Disease

Researchers at the University of Alberta in Canada are working on a saliva test designed to track the trajectory of Alzheimer’s disease prior to the onset of symptoms. Sporadic Alzheimer’s disease is the most common neurodegenerative disorder associated with aging. In its early stages, individuals begin to experience memory loss and cognitive impairments. Currently, there are no treatments available that can reverse the progression of this disease, and the typical diagnostic hallmarks do not emerge until the disease has already manifested.

Focus on Non-Invasive Predictive Techniques

In light of limited success in drug development, recent research has pivoted towards creating non-invasive methods to predict Alzheimer’s disease accurately. The goal is to enable early intervention before clinical symptoms become apparent. Saliva-based detection of disease biomarkers is gaining traction within the research community due to its quick, cost-effective, and non-invasive nature for collecting genomic and metabolomic data.

Importance of Metabolomic Data

Metabolomic data, which may be accessible through saliva, is particularly intriguing because the specific biological pathways contributing to Alzheimer’s remain largely unknown. This type of data mirrors the underlying metabolic processes, allowing researchers to explore differences between Alzheimer’s patients and healthy individuals.

Testing the Newly Developed Saliva Test

Participant Recruitment and Classification

A recent study published in Frontiers in Aging Neuroscience highlights the promising results of the saliva test developed by the University of Alberta team. Participants were recruited from the Victoria Longitudinal Study and from the Glenrose Rehabilitation Hospital in Edmonton, Canada. The research team categorized participants into three groups: 22 individuals diagnosed with Alzheimer’s disease, 35 cognitively normal participants, and 25 with mild cognitive impairment. Classification was conducted over two waves, spaced four-and-a-half years apart, to ensure accuracy.

Sample Collection and Analysis

Participants fasted for an hour before collecting their salivary samples using a DNA self-collection kit provided by the researchers. Employing liquid chromatography-mass spectrometry, the researchers analyzed over 6,000 metabolites from the saliva samples and created a “metabolite panel” to characterize the three participant groups.

Evaluating the Metabolite Panel’s Accuracy

Comparison with Established Risk Factors

To assess the accuracy of the newly identified metabolomics biomarker panels, the researchers utilized machine learning techniques to compare these panels against established Alzheimer’s risk factors. The best predictors distinguishing individuals with Alzheimer’s disease from cognitively normal individuals were found to be memory performance and cognitive speed. Notably, the metabolite panel for the Alzheimer’s group outperformed four genetic variations.

Distinguishing Between Cognitive Groups

When comparing the mild cognitive impairment group to those with Alzheimer’s, the metabolite panels surpassed the predictive capabilities of four genes, educational background, and other risk factors. The panel also proved statistically significant for predicting group membership between mild cognitive impairment and cognitively normal participants, alongside factors such as higher pulse pressure and lower frequency of novel cognitive activities.

Implications for Neurodegenerative Disease Diagnosis

Future Research Directions

While this study is preliminary, the competitive analysis of newly identified metabolite markers against established risk factors presents new opportunities for diagnosing neurodegenerative diseases that are often difficult to detect prior to the appearance of clinical symptoms. Future clinical studies involving a more diverse population, broader age ranges, and larger sample sizes will enhance the validity of the saliva test. If successful, this approach could lead to improved clinical outcomes by allowing clinicians to intervene before cognitive impairments become evident in various neurodegenerative diseases.

References

Huan, T., Tran, T., Zheng, J., Sapkota, S. W., Macdonald, S., Camicioli, R., Dixon, R. A., & Li, L. (2018). Metabolomics Analyses of Saliva Detect Novel Biomarkers of Alzheimer’s Disease. Journal of Alzheimer’s Disease, 65, 1401–1416.
Sapkota, S., Huan, T., Tran, T., Zheng, J., Camicioli, R., Li, L., & Dixon, R. A. (2018). Alzheimer’s Biomarkers From Multiple Modalities Selectively Discriminate Clinical Status: Relative Importance of Salivary Metabolomics Panels, Genetic, Lifestyle, Cognitive, Functional Health, and Demographic Risk Markers. Frontiers in Aging Neuroscience.